2019’s top 15 clinical trial flops (and a flip-flop)
Clinical trials are the most important and expensive step of getting a new drug approved, and it’s no secret that the chances of success are slim. FierceBiotech has drawn up a list of this year’s top 15 trials whose failure they judged to have had material consequences on their sponsors and the patients. Check out the list below:
- Depatux-M
- Elenbecestat
- Emricasan
- Entresto
- Fevipiprant
- Opdivo
- Pexa-Vec
- Praliciguat
- Rapastinel
- ResVax
- Rivipansel
- Rova-T
- SB-913
- Selonsertib
- Toca 511/Toca FC
Flip-flop: Aducanumab
